Advancements in the treatment of pain: not all opioids are the same

Published: May 20, 2024
Abstract Views: 515
PDF: 46
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.


In the heated discourse about the pros and cons of opioids, it is not uncommon to have them discussed as if there are no significant differences among them (except perhaps on the basis of potency, viz., the piperidine fentanyl and its structural analogs such as alfentanil, carfentanil, sufentanil, etc.). It thus seems timely and appropriate to reassess this perception. There are at least three “atypical” opioids approved for clinical use, and another in development, that in one way or another display a more favorable clinical profile than do the “typical” opioids such as morphine, oxycodone, etc.



PlumX Metrics



How to Cite

Advancements in the treatment of pain: not all opioids are the same. (2024). Advancements in Health Research, 1(1).
Lischka A, Lassuthova P, Cakar A, et al. Genetic pain loss disorders. Nat Rev Dis Primers 2022;8:41. DOI:
Bodnar RJ. Endogenous opiates and behavior: 2020. Peptides 2022;151:170752. DOI:
Paul AK, Smith CM, Rahmatullah M, et al. Opioid analgesia and opioid-induced adverse effects: a review. Pharmaceuticals (Basel) 2021;14:1091. DOI:
Stein C. Opioid receptors. Annu Rev Med 2016;67:433-51. DOI:
Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology 2011;115:1363-81. DOI:
Spetea M, Schmidhammer H. Opioids and their receptors: present and emerging concepts in opioid drug discovery. Molecules 2020;25:5658. DOI:
Moayedi M, Davis KD. Theories of pain: from specificity to gate control. J Neurophysiol 2013;109:5-12. DOI:
Nijs J, George SZ, Clauw DJ, et al. Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine. Lancet Rheumatol 2021;3:e383-92. DOI:
Pak DJ, Yong RJ, Kaye AD, Urman RD. Chronification of pain: mechanisms, current understanding, and clinical implications. Curr Pain Headache Rep 2018;22:9. DOI:
Mauceri D. Role of epigenetic mechanisms in chronic pain. Cells 2022;11:2613. DOI:
Guo R, Chen Lh, Xing C, Liu T. Pain regulation by gut microbiota: molecular mechanisms and therapeutic potential. Br J Anaesth 2019;123:637-54. DOI:
Vargas-Schaffer G. Is the who analgesic ladder still valid? Twenty-four years of experience. Can Fam Physician 2010;56:514-7, e202-5.
Kim SJ,Seo JT. Selection of analgesics for the management of acute and postoperative dental pain: a mini-review. J Periodontal Implant Sci 2020;50:68-73. DOI:
Middleton C. Understanding the physiological effects of unrelieved pain. Nurs Times 2003;99:28-31.
Staud R, Robinson ME, Vierck CJ, Jr., Price DD. Diffuse noxious inhibitory controls (dnic) attenuate temporal summation of second pain in normal males but not in normal females or fibromyalgia patients. Pain 2003;101:167-74. DOI:
Millan MJ. Descending control of pain. Prog Neurobiol 2002;66:355-474. DOI:
Somogyi AA, Musolino ST, Barratt DT. New pharmacological perspectives and therapeutic options for opioids: differences matter. Anaesth Intensive Care 2022;50:127-40. DOI:
Gudin J, Fudin J. A narrative pharmacological review of buprenorphine: a unique opioid for the treatment of chronic pain. Pain Ther 2020;9:41-54. DOI:
Reeves RR, Burke RS. Tramadol: basic pharmacology and emerging concepts. Drugs Today (Barc) 2008;44:827-36. DOI:
Romualdi P, Grilli M, Canonico PL, Collino M, Dickenson AH. Pharmacological rationale for tapentadol therapy: a review of new evidence. J Pain Res 2019;12:1513-20. DOI:
Ziemichod W, Kotlinska J, Gibula-Tarlowska E, et al. Cebranopadol as a novel promising agent for the treatment of pain. Molecules 2022;27:3987. DOI:
Terlinden R, Kogel BY, Englberger W, Tzschentke TM. In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol 2010;32:31-8. DOI:
Tzschentke TM, Christoph T, Kogel B, et al. (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol hcl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 2007;323:265-76. DOI:
Schroder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 2011;337:312-20. DOI:
Cowan A, Raffa RB, Tallarida CS, et al. Lack of synergistic interaction between the two mechanisms of action of tapentadol in gastrointestinal transit. Eur J Pain 2014;18:1148-56. DOI:
Freo U, Romualdi P, Kress G. Tapentadol for neuropathic pain: a review of clinical studies. J Pain Res 2019;12:1537-51. DOI:
Robert B. Raffa, Professor Emeritus & Past Chair, Temple University School of Pharmacy, Philadelphia, PA

Adjunct Professor, University of Arizona College of Pharmacy, Tucson, AZ; Co-Founder, Enalare Therapeutics, Inc., Princeton, NJ; CSO, Neumentum Inc., Summit, NJ; Chief Scientist, Advantx Pharmaceuticals Inc., New York, NY, USA

How to Cite

Advancements in the treatment of pain: not all opioids are the same. (2024). Advancements in Health Research, 1(1).

Similar Articles

You may also start an advanced similarity search for this article.